NasdaqGS:MRNABiotechs
Moderna Moves Into Cancer Prevention With UK Lynch Syndrome Trial
UK regulators have authorized a Phase 1/2 trial of Moderna and Oxford's mRNA-4194 preventive cancer vaccine for people with Lynch Syndrome.
The first-in-human study will assess whether an mRNA-based vaccine can help prevent certain cancers in a high-risk genetic population.
This cancer prevention program is part of Moderna's broader collaboration with the UK government on mRNA research.
For investors tracking Moderna (NasdaqGS:MRNA), the move into preventive cancer vaccines adds another...